PATENT CLAIM ANALYSIS

Application Number: 16024333
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["424", "172100"]

Abstract:
The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

Claim (Index 20):
The method of  claim 18 , wherein the subject is further administered a corticosteroid.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 94.0
- Lexical Diversity: 1.97333
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14950748', '16006493', '16006365', '13892671', '16024340']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8325259397118788
- 35 USC 102 Novelty (BERT): 0.6334892726980804
- Combined Prediction Score: 0.8126222730104989
- Mean Citation Score: 657.530412
- Max Citation Score: 716.0033599999997
- Similarity Product: 516.9242552404688

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test